Letter to the Editor Regarding: Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia, Proskorovsky et al. Adv Ther (2019);36(8):2147–2160. doi:10.1007/s12325-019-00991-w

Detalles Bibliográficos
Autores principales: Song, Jinlin, Gao, Wei, Xie, Jipan, Tiwana, Simran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6999160/
https://www.ncbi.nlm.nih.gov/pubmed/31838710
http://dx.doi.org/10.1007/s12325-019-01168-1
_version_ 1783493933293109248
author Song, Jinlin
Gao, Wei
Xie, Jipan
Tiwana, Simran
author_facet Song, Jinlin
Gao, Wei
Xie, Jipan
Tiwana, Simran
author_sort Song, Jinlin
collection PubMed
description
format Online
Article
Text
id pubmed-6999160
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-69991602020-02-19 Letter to the Editor Regarding: Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia, Proskorovsky et al. Adv Ther (2019);36(8):2147–2160. doi:10.1007/s12325-019-00991-w Song, Jinlin Gao, Wei Xie, Jipan Tiwana, Simran Adv Ther Letter Springer Healthcare 2019-12-14 2020 /pmc/articles/PMC6999160/ /pubmed/31838710 http://dx.doi.org/10.1007/s12325-019-01168-1 Text en © The Author(s) 2019 Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Letter
Song, Jinlin
Gao, Wei
Xie, Jipan
Tiwana, Simran
Letter to the Editor Regarding: Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia, Proskorovsky et al. Adv Ther (2019);36(8):2147–2160. doi:10.1007/s12325-019-00991-w
title Letter to the Editor Regarding: Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia, Proskorovsky et al. Adv Ther (2019);36(8):2147–2160. doi:10.1007/s12325-019-00991-w
title_full Letter to the Editor Regarding: Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia, Proskorovsky et al. Adv Ther (2019);36(8):2147–2160. doi:10.1007/s12325-019-00991-w
title_fullStr Letter to the Editor Regarding: Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia, Proskorovsky et al. Adv Ther (2019);36(8):2147–2160. doi:10.1007/s12325-019-00991-w
title_full_unstemmed Letter to the Editor Regarding: Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia, Proskorovsky et al. Adv Ther (2019);36(8):2147–2160. doi:10.1007/s12325-019-00991-w
title_short Letter to the Editor Regarding: Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia, Proskorovsky et al. Adv Ther (2019);36(8):2147–2160. doi:10.1007/s12325-019-00991-w
title_sort letter to the editor regarding: indirect treatment comparison of inotuzumab ozogamicin versus blinatumomab for relapsed or refractory acute lymphoblastic leukemia, proskorovsky et al. adv ther (2019);36(8):2147–2160. doi:10.1007/s12325-019-00991-w
topic Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6999160/
https://www.ncbi.nlm.nih.gov/pubmed/31838710
http://dx.doi.org/10.1007/s12325-019-01168-1
work_keys_str_mv AT songjinlin lettertotheeditorregardingindirecttreatmentcomparisonofinotuzumabozogamicinversusblinatumomabforrelapsedorrefractoryacutelymphoblasticleukemiaproskorovskyetaladvther201936821472160doi101007s1232501900991w
AT gaowei lettertotheeditorregardingindirecttreatmentcomparisonofinotuzumabozogamicinversusblinatumomabforrelapsedorrefractoryacutelymphoblasticleukemiaproskorovskyetaladvther201936821472160doi101007s1232501900991w
AT xiejipan lettertotheeditorregardingindirecttreatmentcomparisonofinotuzumabozogamicinversusblinatumomabforrelapsedorrefractoryacutelymphoblasticleukemiaproskorovskyetaladvther201936821472160doi101007s1232501900991w
AT tiwanasimran lettertotheeditorregardingindirecttreatmentcomparisonofinotuzumabozogamicinversusblinatumomabforrelapsedorrefractoryacutelymphoblasticleukemiaproskorovskyetaladvther201936821472160doi101007s1232501900991w

Ejemplares similares